Inventiva (IVA) Competitors

$5.20 +0.07 (+1.26%)

As of 05/21/2026 04:00 PM Eastern

IVA vs. TNGX, ORKA, ERAS, BEAM, and DNLI

Should you buy Inventiva stock or one of its competitors? MarketBeat compares Inventiva with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Inventiva include Tango Therapeutics (TNGX), Oruka Therapeutics (ORKA), Erasca (ERAS), Beam Therapeutics (BEAM), and Denali Therapeutics (DNLI). These companies are all part of the "pharmaceutical products" industry.

How does Inventiva compare to Tango Therapeutics?

Inventiva (NASDAQ:IVA) and Tango Therapeutics (NASDAQ:TNGX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.

19.1% of Inventiva shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 32.0% of Inventiva shares are held by insiders. Comparatively, 6.5% of Tango Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Tango Therapeutics has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$5.07M	149.98	-$400.67M	N/A	N/A
Tango Therapeutics	$62.38M	50.13	-$101.59M	-$0.83	N/A

Inventiva currently has a consensus target price of $16.56, suggesting a potential upside of 217.76%. Tango Therapeutics has a consensus target price of $32.27, suggesting a potential upside of 49.27%. Given Inventiva's stronger consensus rating and higher probable upside, research analysts plainly believe Inventiva is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
Tango Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64

In the previous week, Tango Therapeutics had 4 more articles in the media than Inventiva. MarketBeat recorded 9 mentions for Tango Therapeutics and 5 mentions for Inventiva. Inventiva's average media sentiment score of 0.59 beat Tango Therapeutics' score of 0.38 indicating that Inventiva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inventiva	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Tango Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Inventiva has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.22, meaning that its share price is 22% more volatile than the broader market.

Inventiva has a net margin of 0.00% compared to Tango Therapeutics' net margin of -151.15%. Inventiva's return on equity of 0.00% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Tango Therapeutics	-151.15%	-41.54%	-33.44%

Summary

Inventiva beats Tango Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Inventiva compare to Oruka Therapeutics?

Inventiva (NASDAQ:IVA) and Oruka Therapeutics (NASDAQ:ORKA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

Inventiva's return on equity of 0.00% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Oruka Therapeutics	N/A	-26.16%	-25.00%

Oruka Therapeutics has lower revenue, but higher earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$5.07M	149.98	-$400.67M	N/A	N/A
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A

Inventiva presently has a consensus target price of $16.56, suggesting a potential upside of 217.76%. Oruka Therapeutics has a consensus target price of $120.80, suggesting a potential upside of 105.83%. Given Inventiva's stronger consensus rating and higher possible upside, research analysts plainly believe Inventiva is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

19.1% of Inventiva shares are owned by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are owned by institutional investors. 32.0% of Inventiva shares are owned by insiders. Comparatively, 23.5% of Oruka Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Oruka Therapeutics had 14 more articles in the media than Inventiva. MarketBeat recorded 19 mentions for Oruka Therapeutics and 5 mentions for Inventiva. Inventiva's average media sentiment score of 0.59 beat Oruka Therapeutics' score of 0.55 indicating that Inventiva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inventiva	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Oruka Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inventiva has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.2, indicating that its stock price is 120% less volatile than the broader market.

Summary

Inventiva beats Oruka Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Inventiva compare to Erasca?

Erasca (NASDAQ:ERAS) and Inventiva (NASDAQ:IVA) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability.

In the previous week, Erasca had 8 more articles in the media than Inventiva. MarketBeat recorded 13 mentions for Erasca and 5 mentions for Inventiva. Inventiva's average media sentiment score of 0.59 beat Erasca's score of -0.36 indicating that Inventiva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	0 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
Inventiva	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

67.8% of Erasca shares are held by institutional investors. Comparatively, 19.1% of Inventiva shares are held by institutional investors. 14.2% of Erasca shares are held by insiders. Comparatively, 32.0% of Inventiva shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Erasca presently has a consensus price target of $18.75, suggesting a potential upside of 61.64%. Inventiva has a consensus price target of $16.56, suggesting a potential upside of 217.76%. Given Inventiva's stronger consensus rating and higher possible upside, analysts plainly believe Inventiva is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10

Inventiva's return on equity of 0.00% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-35.31%	-29.49%
Inventiva	N/A	N/A	N/A

Erasca has higher earnings, but lower revenue than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A
Inventiva	$5.07M	149.98	-$400.67M	N/A	N/A

Erasca has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market. Comparatively, Inventiva has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market.

Summary

Inventiva beats Erasca on 9 of the 13 factors compared between the two stocks.

How does Inventiva compare to Beam Therapeutics?

Inventiva (NASDAQ:IVA) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

19.1% of Inventiva shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 32.0% of Inventiva shares are owned by insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Inventiva has a net margin of 0.00% compared to Beam Therapeutics' net margin of -39.66%. Inventiva's return on equity of 0.00% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Beam Therapeutics	-39.66%	-29.00%	-22.61%

Beam Therapeutics has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$5.07M	149.98	-$400.67M	N/A	N/A
Beam Therapeutics	$139.74M	20.37	-$79.99M	-$0.68	N/A

Inventiva presently has a consensus target price of $16.56, suggesting a potential upside of 217.76%. Beam Therapeutics has a consensus target price of $46.83, suggesting a potential upside of 69.26%. Given Inventiva's stronger consensus rating and higher probable upside, research analysts clearly believe Inventiva is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

Inventiva has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.26, suggesting that its stock price is 126% more volatile than the broader market.

In the previous week, Beam Therapeutics had 15 more articles in the media than Inventiva. MarketBeat recorded 20 mentions for Beam Therapeutics and 5 mentions for Inventiva. Inventiva's average media sentiment score of 0.59 beat Beam Therapeutics' score of -0.51 indicating that Inventiva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inventiva	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Beam Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Summary

Inventiva beats Beam Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Inventiva compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Inventiva (NASDAQ:IVA) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

In the previous week, Inventiva had 3 more articles in the media than Denali Therapeutics. MarketBeat recorded 5 mentions for Inventiva and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.76 beat Inventiva's score of 0.59 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Inventiva	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Denali Therapeutics has a beta of 0.99, indicating that its stock price is 1% less volatile than the broader market. Comparatively, Inventiva has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market.

92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 19.1% of Inventiva shares are owned by institutional investors. 12.5% of Denali Therapeutics shares are owned by company insiders. Comparatively, 32.0% of Inventiva shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Inventiva has lower revenue, but higher earnings than Denali Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	9.27	-$512.54M	-$2.88	N/A
Inventiva	$5.07M	149.98	-$400.67M	N/A	N/A

Inventiva's return on equity of 0.00% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-52.20%	-43.86%
Inventiva	N/A	N/A	N/A

Denali Therapeutics currently has a consensus price target of $35.00, suggesting a potential upside of 81.35%. Inventiva has a consensus price target of $16.56, suggesting a potential upside of 217.76%. Given Inventiva's stronger consensus rating and higher probable upside, analysts clearly believe Inventiva is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10

Summary

Inventiva beats Denali Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Inventiva News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IVA vs. The Competition

Export

Metric	Inventiva	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$750.19M	$3.34B	$6.35B	$12.29B
Dividend Yield	N/A	2.29%	2.79%	5.33%
P/E Ratio	N/A	18.53	21.08	25.34
Price / Sales	149.98	286.26	528.17	80.04
Price / Cash	N/A	129.82	44.13	56.16
Price / Book	-23.68	6.92	10.00	7.01
Net Income	-$400.67M	$24.39M	$3.55B	$335.27M
7 Day Performance	-4.23%	2.68%	1.99%	1.28%
1 Month Performance	-0.76%	-1.45%	-0.87%	0.16%
1 Year Performance	66.45%	62.18%	36.38%	34.54%

Inventiva Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IVA Inventiva	3.1893 of 5 stars	$5.21 +1.4%	$16.56 +217.8%	+67.5%	$750.19M	$5.07M	N/A	100	News Coverage
TNGX Tango Therapeutics	2.7232 of 5 stars	$23.08 -1.7%	$22.44 -2.7%	+1,043.9%	$3.32B	$62.38M	N/A	90
ORKA Oruka Therapeutics	3.6127 of 5 stars	$63.81 -2.9%	$120.80 +89.3%	+454.7%	$3.20B	N/A	N/A	N/A	Trending News Analyst Revision
ERAS Erasca	3.4841 of 5 stars	$10.22 -2.1%	$18.75 +83.5%	+850.8%	$3.17B	N/A	N/A	120
BEAM Beam Therapeutics	3.5195 of 5 stars	$30.79 -3.0%	$47.17 +53.2%	+60.7%	$3.16B	$139.74M	N/A	510	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IVA) was last updated on 5/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inventiva (IVA) Competitors

IVA vs. TNGX, ORKA, ERAS, BEAM, and DNLI

How does Inventiva compare to Tango Therapeutics?

Summary

How does Inventiva compare to Oruka Therapeutics?

Summary

How does Inventiva compare to Erasca?

Summary

How does Inventiva compare to Beam Therapeutics?

Summary

How does Inventiva compare to Denali Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IVA vs. The Competition

Inventiva Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Inventiva (IVA) Competitors

IVA vs. TNGX, ORKA, ERAS, BEAM, and DNLI

How does Inventiva compare to Tango Therapeutics?

Do insiders and institutionals hold more shares of IVA or TNGX?

Which has stronger earnings and valuation, IVA or TNGX?

Do analysts rate IVA or TNGX?

Does the media favor IVA or TNGX?

Which has more volatility and risk, IVA or TNGX?

Is IVA or TNGX more profitable?

Summary

How does Inventiva compare to Oruka Therapeutics?

Is IVA or ORKA more profitable?

Which has stronger valuation & earnings, IVA or ORKA?

Do analysts prefer IVA or ORKA?

Do insiders & institutionals hold more shares of IVA or ORKA?

Does the media prefer IVA or ORKA?

Which has more risk and volatility, IVA or ORKA?

Summary

How does Inventiva compare to Erasca?

Does the media favor ERAS or IVA?

Do institutionals and insiders hold more shares of ERAS or IVA?

Do analysts rate ERAS or IVA?

Is ERAS or IVA more profitable?

Which has higher valuation & earnings, ERAS or IVA?

Which has more volatility & risk, ERAS or IVA?

Summary

How does Inventiva compare to Beam Therapeutics?

Do institutionals & insiders hold more shares of IVA or BEAM?

Is IVA or BEAM more profitable?

Which has higher valuation & earnings, IVA or BEAM?

Do analysts rate IVA or BEAM?

Which has more volatility and risk, IVA or BEAM?

Does the media prefer IVA or BEAM?

Summary

How does Inventiva compare to Denali Therapeutics?

Does the media refer more to DNLI or IVA?

Which has more volatility & risk, DNLI or IVA?

Do institutionals and insiders have more ownership in DNLI or IVA?

Which has better valuation & earnings, DNLI or IVA?

Is DNLI or IVA more profitable?

Do analysts recommend DNLI or IVA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IVA vs. The Competition

Inventiva Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools